Clinical trials: PCS
Pain, Postoperative
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores
This is a multiple center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection administered intrathecally before surgery in patients with high Pain Catastrophizing Scale…
- Trial name
- NCT04104919
- Testing
- Brivoligide Injection 660 mg/6 mL
- Sponsor
- Adynxx, Inc.
Post-Concussion Syndrome
ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion
This is a Phase 1 Clinical Safety Study intended to provide preliminary assessments of the safety, tolerability, and clinical alleviation of symptoms associated with Post Concussion Syndrome (PCS), also known as Chronic…
- Trial name
- NCT04744051
- Testing
- 50 Adipose Derived Stem Cell Infusion, 150 Adipose Derived Stem Cell Infusion, 300 Adipose Derived Stem Cell Infusion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- American CryoStem Corporation
Pain, Postoperative
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores
This is a multi-center, Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection administered intrathecally before surgery in patients with a Pain Catastrophizing…
- Trial name
- NCT03797612
- Testing
- Brivoligide Injection 660 mg/6 mL
- Where
- 2 sites in United States
- Sponsor
- Adynxx, Inc.
Apheresis Related Hypotension
IMPACT (Improving Plasma Collection) Clinical Trial
Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.
- Trial name
- IMPACT (NCT04320823)
- Testing
- Updated Plasma Collection Feature, Current Plasma Collection Approach
- Where
- 3 sites in United States
- Volunteers
- 3,443 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Long COVID
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.
- Trial name
- IMPACT-LC (NCT06974084)
- Testing
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- HealthBio, Inc.